Novo Nordisk Pharmatech A/S enters Russia/CIS distribution agreement with IMCoPharma

Koege, Denmark: – World-leading Recombinant Insulin and quaternary ammonium compounds (Quats) specialist Novo Nordisk Pharmatech A/S has reached an agreement with IMCoPharma a.s. in the Czech Republic to distribute pharmaceutical grade quaternary ammonium compounds (Quats) to Russian and Commonwealth of Independent States (CIS) healthcare markets.

Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in Quats (Benzalkonium Chloride, Cetyl Trimethyl Ammonium Bromide (CTAB) and Cetrimide) used as active pharmaceutical ingredients (APIs) and excipients in the highest available quality standards, along with Recombinant Insulin for use in cell culture media to enhance cell growth, viability and productivity.

The products comply with the latest pharmacopeial standards and are extensively supported by CEPs, DMFs and a comprehensive regulatory and quality assurance document package. In addition, the manufacturing site in Køge (Denmark) is audited by the Danish Medicines Agency and US FDA.

Exceptional healthcare products

Gernot Stadlmann, Sales & Marketing Director at Novo Nordisk Pharmatech, commented:

“For many years, we have been trying to find a strong partner for the Russian market who can also service CIS countries. So we are pleased that we have now entered into a partnership with IMCoPharma, who will extend our very high standards and good distribution practice to these markets. We all look forward to a successful collaboration in the years to come.”

For IMCoPharma, Commercial Director Lukas Adamec added: “I am very happy for our collaboration with Novo Nordisk Pharmatech, which started already at the end of 2020 in several CIS countries. We are proud to be a partner of an experienced European company with exceptional healthcare products and to represent their product portfolio among our customers across Eastern Europe and Middle Asian countries”.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then.

Novo Nordisk Pharmatech A/S is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharma and biopharmaceutical industries.

Learn more at: https://novonordiskpharmatech.com

About IMCoPharma

IMCoPharma, since 2020 a part of Barentz group, is a leading distributor of ingredients in the life science markets. From its base in Bílovec, Czechia, the company deals with the transfer of APIs and excipients primarily from the EU to all CIS countries and Ukraine. Forming a bridge between the CIS region and the rest of the world for over 25 years, the company has become a strong and reliable partner for suppliers and customers.

IMCoPharma’s subsidiaries and representative offices are located in Russia, Ukraine, Belarus, Uzbekistan, and Kazakhstan.

In addition to key distribution and warehousing services, IMCoPharma also provides sampling services, licensing, contract manufacturing, transfer of technology and regulatory and R&D support in different markets.

Learn more at: https://www.imcopharma.com

Resources

Click on Novo Nordisk Pharmatech News for more developments at Novo Nordisk Pharmatech.
Click on ImCoPharma Corporate video to watch on YouTube.